Cargando…
Prevalence, causes and impact of TP53-loss phenocopying events in human tumors
BACKGROUND: TP53 is a master tumor suppressor gene, mutated in approximately half of all human cancers. Given the many regulatory roles of the corresponding p53 protein, it is possible to infer loss of p53 activity – which may occur due to alterations in trans – from gene expression patterns. Severa...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127307/ https://www.ncbi.nlm.nih.gov/pubmed/37095494 http://dx.doi.org/10.1186/s12915-023-01595-1 |
_version_ | 1785030437057331200 |
---|---|
author | Fito-Lopez, Bruno Salvadores, Marina Alvarez, Miguel-Martin Supek, Fran |
author_facet | Fito-Lopez, Bruno Salvadores, Marina Alvarez, Miguel-Martin Supek, Fran |
author_sort | Fito-Lopez, Bruno |
collection | PubMed |
description | BACKGROUND: TP53 is a master tumor suppressor gene, mutated in approximately half of all human cancers. Given the many regulatory roles of the corresponding p53 protein, it is possible to infer loss of p53 activity – which may occur due to alterations in trans – from gene expression patterns. Several such alterations that phenocopy p53 loss are known, however additional ones may exist, but their identity and prevalence among human tumors are not well characterized. RESULTS: We perform a large-scale statistical analysis on transcriptomes of ~ 7,000 tumors and ~ 1,000 cell lines, estimating that 12% and 8% of tumors and cancer cell lines, respectively, phenocopy TP53 loss: they are likely deficient in the activity of the p53 pathway, while not bearing obvious TP53 inactivating mutations. While some of these cases are explained by amplifications in the known phenocopying genes MDM2, MDM4 and PPM1D, many are not. An association analysis of cancer genomic scores jointly with CRISPR/RNAi genetic screening data identified an additional common TP53-loss phenocopying gene, USP28. Deletions in USP28 are associated with a TP53 functional impairment in 2.9–7.6% of breast, bladder, lung, liver and stomach tumors, and have comparable effect size to MDM4 amplifications. Additionally, in the known copy number alteration (CNA) segment harboring MDM2, we identify an additional co-amplified gene (CNOT2) that may cooperatively boost the TP53 functional inactivation effect of MDM2. An analysis of cancer cell line drug screens using phenocopy scores suggests that TP53 (in)activity commonly modulates associations between anticancer drug effects and various genetic markers, such as PIK3CA and PTEN mutations, and should thus be considered as a drug activity modifying factor in precision medicine. As a resource, we provide the drug-genetic marker associations that differ depending on TP53 functional status. CONCLUSIONS: Human tumors that do not bear obvious TP53 genetic alterations but that phenocopy p53 activity loss are common, and the USP28 gene deletions are one likely cause. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12915-023-01595-1. |
format | Online Article Text |
id | pubmed-10127307 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101273072023-04-26 Prevalence, causes and impact of TP53-loss phenocopying events in human tumors Fito-Lopez, Bruno Salvadores, Marina Alvarez, Miguel-Martin Supek, Fran BMC Biol Research Article BACKGROUND: TP53 is a master tumor suppressor gene, mutated in approximately half of all human cancers. Given the many regulatory roles of the corresponding p53 protein, it is possible to infer loss of p53 activity – which may occur due to alterations in trans – from gene expression patterns. Several such alterations that phenocopy p53 loss are known, however additional ones may exist, but their identity and prevalence among human tumors are not well characterized. RESULTS: We perform a large-scale statistical analysis on transcriptomes of ~ 7,000 tumors and ~ 1,000 cell lines, estimating that 12% and 8% of tumors and cancer cell lines, respectively, phenocopy TP53 loss: they are likely deficient in the activity of the p53 pathway, while not bearing obvious TP53 inactivating mutations. While some of these cases are explained by amplifications in the known phenocopying genes MDM2, MDM4 and PPM1D, many are not. An association analysis of cancer genomic scores jointly with CRISPR/RNAi genetic screening data identified an additional common TP53-loss phenocopying gene, USP28. Deletions in USP28 are associated with a TP53 functional impairment in 2.9–7.6% of breast, bladder, lung, liver and stomach tumors, and have comparable effect size to MDM4 amplifications. Additionally, in the known copy number alteration (CNA) segment harboring MDM2, we identify an additional co-amplified gene (CNOT2) that may cooperatively boost the TP53 functional inactivation effect of MDM2. An analysis of cancer cell line drug screens using phenocopy scores suggests that TP53 (in)activity commonly modulates associations between anticancer drug effects and various genetic markers, such as PIK3CA and PTEN mutations, and should thus be considered as a drug activity modifying factor in precision medicine. As a resource, we provide the drug-genetic marker associations that differ depending on TP53 functional status. CONCLUSIONS: Human tumors that do not bear obvious TP53 genetic alterations but that phenocopy p53 activity loss are common, and the USP28 gene deletions are one likely cause. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12915-023-01595-1. BioMed Central 2023-04-24 /pmc/articles/PMC10127307/ /pubmed/37095494 http://dx.doi.org/10.1186/s12915-023-01595-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Fito-Lopez, Bruno Salvadores, Marina Alvarez, Miguel-Martin Supek, Fran Prevalence, causes and impact of TP53-loss phenocopying events in human tumors |
title | Prevalence, causes and impact of TP53-loss phenocopying events in human tumors |
title_full | Prevalence, causes and impact of TP53-loss phenocopying events in human tumors |
title_fullStr | Prevalence, causes and impact of TP53-loss phenocopying events in human tumors |
title_full_unstemmed | Prevalence, causes and impact of TP53-loss phenocopying events in human tumors |
title_short | Prevalence, causes and impact of TP53-loss phenocopying events in human tumors |
title_sort | prevalence, causes and impact of tp53-loss phenocopying events in human tumors |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127307/ https://www.ncbi.nlm.nih.gov/pubmed/37095494 http://dx.doi.org/10.1186/s12915-023-01595-1 |
work_keys_str_mv | AT fitolopezbruno prevalencecausesandimpactoftp53lossphenocopyingeventsinhumantumors AT salvadoresmarina prevalencecausesandimpactoftp53lossphenocopyingeventsinhumantumors AT alvarezmiguelmartin prevalencecausesandimpactoftp53lossphenocopyingeventsinhumantumors AT supekfran prevalencecausesandimpactoftp53lossphenocopyingeventsinhumantumors |